BioTelemetry Inc. (NASDAQ:BEAT) shares traded down 2.8% on Monday . The company traded as low as $17.05 and last traded at $17.32, with a volume of 171,765 shares changing hands. The stock had previously closed at $17.81.

Separately, Zacks Investment Research lowered shares of BioTelemetry from a “hold” rating to a “sell” rating in a research note on Tuesday, April 19th.

The firm has a market cap of $483.68 million and a price-to-earnings ratio of 43.90. The company has a 50 day moving average price of $16.64 and a 200 day moving average price of $13.55.

BioTelemetry (NASDAQ:BEAT) last posted its quarterly earnings results on Tuesday, April 26th. The company reported $0.20 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.10 by $0.10. The firm had revenue of $48.60 million for the quarter, compared to analysts’ expectations of $46.54 million. During the same quarter in the previous year, the firm posted $0.06 EPS. The firm’s revenue for the quarter was up 12.0% compared to the same quarter last year. On average, equities research analysts forecast that BioTelemetry Inc. will post $0.71 EPS for the current year.

A number of hedge funds have recently bought and sold shares of the stock. Gabelli Funds LLC purchased a new stake in BioTelemetry during the fourth quarter valued at $1,190,000. Russell Frank Co increased its stake in BioTelemetry by 58.9% in the fourth quarter. Russell Frank Co now owns 249,457 shares of the company’s stock valued at $2,933,000 after buying an additional 92,455 shares during the last quarter. 1492 Capital Management LLC increased its stake in BioTelemetry by 11.4% in the fourth quarter. 1492 Capital Management LLC now owns 321,761 shares of the company’s stock valued at $3,758,000 after buying an additional 32,932 shares during the last quarter. Royce & Associates LLC increased its stake in BioTelemetry by 102.2% in the fourth quarter. Royce & Associates LLC now owns 606,700 shares of the company’s stock valued at $7,086,000 after buying an additional 306,700 shares during the last quarter. Finally, Wells Fargo & Company MN increased its stake in BioTelemetry by 13.6% in the fourth quarter. Wells Fargo & Company MN now owns 994,163 shares of the company’s stock valued at $11,612,000 after buying an additional 119,328 shares during the last quarter.

BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.